Type to search

Agribusiness Manufacturing & Distribution News

Wilmington company enters fast emerging market in cannabinoids

Avatar photo

The pharmaceutical company Noramco, headquartered on the Wilmington riverfront, has signed a letter of intent with Teewinot Life Sciences to produce pharmaceutical-grade cannabinoids, the chemical compounds in cannabis flowers and a component of marijuana. 

Noramco specializes in producing active pharmaceutical ingredients, or biologically active materials, from controlled substances. The agreement gives Noramco access to Tweewinot’s proprietary CannSynthesis process, which produces pure cannabinoids through biocatalysis.

The goal is to provide a source for large quantities of “cannabinoid-based reference materials” outside of plant extraction, according to Jeffrey M. Korentur, president and CEO of Tweewinot Life Sciences.

Noramco plans to use the process to enter the growing market surrounding cannabis and cannabis-derived products.

“Combining Teewinot’s CannSynthesis technology with Noramco’s controlled substance manufacture and distribution expertise allows us to serve a fast emerging market space,” said James Mish, President and CEO of Noramco.

Get the free DBT email newsletter  

Follow the people, companies and issues that matter most to business in Delaware.


You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *

Premier Digital Partners

© 2024 Delaware Business Times

Flash Sale! Subscribe to Delaware Business Times and save 50%.

Limited time offer. New subscribers only.

Limited time offer. New subscribers only.


Subscribe to Delaware Business Times and save 50%